ALX Oncology (ALXO) vs Minerva Neurosciences (NERV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Minerva Neurosciences (NERV) has outperformed ALX Oncology (ALXO) over the past year, gaining 23.7% versus a loss of 35.6%. Over five years, NERV leads with a -70.6% price change compared with -97.9% for ALXO. ALX Oncology is the larger company by market cap ($172.8 million vs $151.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALXO | NERV |
|---|---|---|
| Share price | $1.25 | $3.18 |
| Market cap | $172.85M | $151.84M |
| 1-day change | +5.93% | -1.24% |
| YTD return | +10.62% | -20.90% |
| 1-year return | -35.57% | +23.74% |
| 5-year return | -97.88% | -70.56% |
| EPS (TTM) | $-1.13 | $-36.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.66 | $12.46 |
| 52-week low | $1.05 | $2.24 |
| Distance from 52-week high | -53.01% | -74.48% |
| Analyst consensus | none | none |
| Avg. price target upside | +268.00% | +224.84% |
| Average volume | 1.04M | 183.63K |
| Shares outstanding | 138.28M | 47.75M |
| Employees | 48 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NERV has outperformed ALXO by 59.3 percentage points over the past year.
About ALX Oncology
ALXO stock →ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Minerva Neurosciences
NERV stock →Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
ALXO vs NERV FAQ
Which is bigger, ALX Oncology or Minerva Neurosciences?
ALX Oncology (ALXO) is larger, with a market capitalization of $172.85M compared with $151.84M for Minerva Neurosciences (NERV).
Which stock has performed better over the past year, ALXO or NERV?
NERV returned +23.74% over the past 12 months, compared with -35.57% for ALXO (price return, excluding dividends). Past performance does not predict future results.
Are ALX Oncology and Minerva Neurosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.